

About Albemarle Asset Management


Albemarle Asset Management was founded in London in 2003. The company provides both individual and collective management services for private and institutional investors, financial and capital management consultancy, and managed investment solutions. Our services cover global financial markets and our expertise enables us to offer diverse set of investment instruments and strategies.

ooracogree.


Performance

	YTD	1M	3YR	5YR	Inception
Fund	4.87%	4.68%	20.61%	90.54%	330.82%
	Best Mth	Worst Mth	CAGR		
Fund	21.20%	-24.16%	9.45%		

Chart Performance



Returns



Fund Objective

White Rhino is an Alternative Investment Fund incorporated in Ireland. The objective of the subfund is to achieve medium-long term outperformance compared to the benchmark.

Fund Information

Currency

Company Albemarle Alternative Funds PLC Investment Albemarle Asset Management Ltd

Bloomberg AAAWRNO ID
ISIN IE00B4W71478
Inception 20/03/2008

Fund Manager Albemarle Asset Management Ltd

Management Fees 1.00% p.a.

Performance Fee 10% over High Watermark

EUR

Cut-off subs T-1 bus days before 2:30 pm
Cut-off reds T-30 bus days before 2:30 pm

NAV Weekly

Stlmt date for T+2 Irish Business Days
Stlmt date for T+5 Irish Business Days

Domicile Ireland

Auditors Grant Thornton

Depositary Northern Trust Fiduciary Services

(Ireland) Ltd

Category QIAIF

Award



Best Performance Macro under \$500m

Important Information


The information contained within this document is for the use of Institutional and Professional Investors only

* Data source: Bloomberg

Different Share Classes


Class	NAV	YTD	1M	1YR	Since Incep	ti Inception Date	Management I	Fe Bloomberg ID
В	102.72	4.56%	4.37%	5.89%	21.15%	04/03/2022	1.00% p.a.	AAAWRNB ID






Top Holdings

Total	43.42%
ARNOLDO MONDADORI EDITORE	4.81%
FLUIDRA SA	5.43%
FILA SPA	8.83%
ESPRINET SPA	10.09%
ELAIA SPA	14.26%







Commentary

The Fund posted a positive result in March, in line with the performance registered by the main equity indexes. The main positive contributors to the Fund performance had been El.En, Piovan, Mondadori, Esprinet and Cementir. El.En jumped as the producer of laser devices posted convincing Q4 2023 results and issued a 2024 guidance above analysts expectations thanks to the solid outlook for the Medical division. Piovan outperformed as the company reported FY 2023 results above expectations and communicated a 2024 outlook which entails another year of growing profits. Mondadori rose as the book publisher announced solid FY 2023 results and issued 2024 guidance and 3-year financial targets above expectations. The main detractors to the Fund performance had been Fila, Aeffe and Ariston. Fila fell as the company released underwhelming Q4 and FY 2023 results and the announced 2024 guidance was slightly below expectations. Aeffe underperformed as the company presented negative 2023 results, burdened by the restructuring and reorganization of Moschino business amid a general slowdown of the luxury sector. During the month the main trades executed had been the sale of Stellantis, Fluidra and Piovan, and the purchase of Ariston, Diasorin, El.En, Jungheinrich and Luve.

Disclaimer

This information is being communicated by Albemarle Asset Management Limited, which is authorised and regulated by the Financial Conduct Authority. This material is for information only and does not constitute an offer or recommendation to buy or sell any investment, or subscribe to any investment management or advisory service. It is only directed and may only be distributed to persons who are Professional Clients or Eligible Counterparties and is not, under any circumstances, intended for distribution to the general public. With investment, your capital is at risk and the value of an investment and the income from it can go up as well as down, it may be affected by exchange rate variations and you may not get back the amount invested. Past performance is not necessarily a guide to future performance. We do not represent that this information, including any third party information, is accurate or complete and it should not be relied upon as such. Opinions expressed herein reflect the opinion of Albemarle Asset Management Limited and are subject to change without notice. No part of this document may be reproduced in any manner without the written permission of Albemarle Asset Management Limited, however recipients may pass on this document but only to others falling within this category. This information should be read in conjunction with the relevant fund documentation which may include the fund's prospectus, simplified prospectus or supplement documentation and if you are unsure if any of the products and portfolios featured are the right choice for you, please seek independent financial advice provided by regulated third parties.